Illumina, Inc. (ILMN) Earnings Call Transcript & Summary

February 11, 2021

NASDAQ US Health Care Life Sciences Tools and Services earnings 60 min

Earnings Call Speaker Segments

Juliet Cunningham

executive
#1

Welcome, everybody, and thank you for being here on this call covering both the fourth quarter and the entire 2020 fiscal year. During this session, we'll review the financial figures that came out once trading had ended, share some perspective on how our commercial operations performed, and then open things up for questions and answers. Should you not have had a chance to look over the earnings release yet, it's available on our website, illumina.com, under the Investor Relations tab. Representing Illumina today are Francis deSouza, our CEO, and Sam Samad, our CFO. Francis is going to speak about where Illumina's business currently stands, while Sam will walk everyone through the financial numbers. This session is being captured, and a recording of the audio will be stored in the Investors area of our site. We intend for every forward-looking statement about our financial performance and business activity that is shared on this call to receive protection under the Private Securities Litigation Reform Act of 1995. Such statements carry risks and uncertainties, and what actually happens or what we actually achieve could differ substantially from what is anticipated or covered here. Every forward-looking statement rests on information available right now, and Illumina takes on no duty to revise any of them. For a clearer picture of the risks and uncertainties that might make actual results come out differently, please look at the filings Illumina makes with the Securities and Exchange Commission — among them Illumina's latest Forms 10-Q and 10-K. Having said that, I'll hand the call over now to Francis.

Francis deSouza

executive
#2

Thanks, Juliet. Everyone, good afternoon. 2020 ended on a high note for Illumina, since revenue and orders each reached all-time highs. Revenue during the fourth quarter came to $953 million, a sequential gain of 20% over the third quarter. Sequencing instruments rose 29% quarter-over-quarter. Additionally, we recorded our second-highest NovaSeq unit volume in the fourth quarter, largely fueled by the August release of our v1.5 reagents. The v1.5 launch produced stronger growth in new customers plus more HiSeq conversions. As it reaches its 5th year on the market, NovaSeq remains the sequencer with the leading market position. For all of 2020, revenue of $3.2 billion fell 9% versus the prior year, and the biggest hit came from the pandemic during the second quarter. Our business gained momentum across the second half, which expanded 17% relative to the first half. During 2020, we delivered over 2,000 sequencing systems, another record for mid-throughput shipments, and brought in more than 700 new customers, surpassing what we had anticipated. Let me offer a few fourth quarter highlights by platform, beginning with our high throughput systems. NovaSeq consumable pull-through reached its top level for the year, exceeding $1.2 million per instrument. For 2021, we anticipate NovaSeq flow-through will stay at pre-pandemic levels of $1.1 million to $1.2 million per year. Introducing the NovaSeq v1.5 reagent is sparking a fresh wave of high-throughput customers now that a $600 genome has become achievable for labs regardless of size; in fact, more than half of our NovaSeq system orders during 2020 came from new high-throughput customers. Among them is Argentina's Ministry of Health, which bought NovaSeq for infectious disease research. The v1.5 introduction likewise shortened the purchasing time line for CellCarta, a contract research organization and a new to high-throughput customer that intends to use its NovaSeq to support oncology clinical trials. The v1.5 reagents are additionally bolstering the economic rationale for legacy HiSeq customers to upgrade, such as the University of Oregon, which is using NovaSeq for large, single cell and epigenetic studies. We closed the year with roughly 1,000 active HiSeq units; and during 2021, we anticipate continued HiSeq to NovaSeq adoption among the 320 customers yet to transition. Turning to mid-throughput. 2020 represented the second straight year of record placements, and the mid-throughput segment keeps delivering durable growth in our core business. Fourth quarter strength came mainly from the successful launches of NextSeq 1000 and 2000, which also lifted mid-throughput consumables revenue for the full year. Going forward, we anticipate continued NextSeq expansion in 2021, especially in the clinical segment. Notably, we received NMPA approval in China for NextSeqDx, driving demand in local hospitals and applications like oncology and infectious disease testing; we expect this approval to drive NextSeqDx placements and further increase our clinical presence in 2021; we added more than 500 new low-throughput customers in 2020, bringing our total to more than 6,100 customers worldwide. Our platforms support the widest array of flow cell configurations and the broadest range of supported methods, with run times reaching as little as 5 hours. During Q4, we achieved record revenue in low-throughput consumables, fueled by clients such as Invitae using MiSeqDX for products under development. Now I'll share updates regarding our clinical, research, and applied segments. Sequencing consumables revenue totaled $2 billion, a decline of 2% compared to the prior year, which mirrors how the pandemic affected academic and research organizations. Come Q4 2020, clinical sequencing run rates had actually surpassed levels seen before the pandemic, while research run rates similarly recovered to normal pre-pandemic volumes; witnessing our customers bounce back so effectively amid such difficult conditions was truly encouraging. Over 43% of sequencing consumable shipments during 2020 went to clinical customers, encompassing testing for oncology, reproductive health, and genetic disease. Clinical testing remained resilient throughout the pandemic, as clinical consumables rose roughly 8% year-over-year to around $890 million in 2020. Furthermore, during Q4, growth in clinical consumables sped up to more than 20% year-over-year. On the clinical side, I want to first emphasize the enormous strides achieved in market access and reimbursement. We think these recent landmark coverage choices will push adoption of next-generation sequencing to unprecedented heights across the coming years. In oncology, tumor-comprehensive genomic profiling is now covered for 205 million lives within the U.S. And as targeted oncology therapies multiply, we anticipate CGP expanding into a market worth over $1 billion by 2026. In addition, Germany has begun covering tumor CGP along with whole exome and whole genome for rare and undiagnosed genetic disease, with no restrictions. This translates to 73 million lives gaining improved access to CGP plus whole exome and whole genome testing. In reproductive health, as several major payers broaden coverage to all pregnancies, we anticipate NIPT coverage within the U.S. surpassing 3 million pregnancies by the close of 2021; lastly, whole genome sequencing coverage for genetic disease testing rose tenfold during 2020; and we foresee WGS turning into the standard of care for genetic disease as awareness and reimbursement keep expanding. With those favorable reimbursement shifts serving as a foundation, I'll now go into our clinical focus areas with a bit more depth. Oncology testing remains at roughly 20% of overall sequencing consumables, and it increased year-over-year thanks to firms such as Guardant Health, which broadened its mobile phlebotomy offerings to assist patients in reaching its Guardant360 liquid biopsy test throughout the pandemic. This also encompasses Genomic Health and the NHS, which embraced NovaSeq comprehensive genomic profiling as a standard of care in the U.K.; plus oncology centers such as Florida Cancer Specialists, a private community oncology and hematology practice, operating close to 100 offices across Florida. Florida Cancer Specialists bought several NextSeqDx systems during 2020 to conduct Illumina's TruSight Oncology 500 assay within its new lab. Reproductive health accounted for roughly 12% of sequencing consumables, with revenue and samples for our end-to-end VeriSeq NIPT solution climbing over 20% in 2020. Finally, roughly 10% of the money we bring in from sequencing consumables comes from tests for genetic disease. When it comes to this field, customers keep picking Illumina because our sequencers are extremely accurate and can scale up. Take, for instance, the collaboration that was announced recently involving Weill Cornell Medicine, New York-Presbyterian Hospital, and the New York Genome Center — they'll be applying Illumina technology for clinical WGS in areas such as cardiovascular, metabolic and neurodegenerative diseases. Now moving to our research and applied segment. That brought in around $1.2 billion, which was just under 57% of the sequencing consumables we shipped, and it declined by roughly 6% compared with a year earlier, since the pandemic hit our customers hard. Research picked up speed during the second half, posting 20% growth relative to the first half, as researchers made their way back to their labs. This segment covers research into oncology and genetic disease, plus population genomic and research initiatives. There are programs our sequencers have enabled, such as K-DNA, a big Korean effort with the goal of sequencing 1 million genomes by 2030. A consortium of service providers that standardized on Illumina technology came out on top in the competitive tender, thanks to NovaSeq's stronger technical evaluation. That program intends to wrap up a 7,500-genome Phase I before this year ends. During the fourth quarter, the NHS began a phased rollout of whole genome sequencing for certain rare disease and cancer patients as part of their routine care. After this live clinical testing phase wraps up, we anticipate the whole genome sequencing service will ramp up further in the spring. We anticipate the All of Us program will keep scaling this year; and the NIH expects to release de-identified data from 100,000 sequence and array genotype samples to its research portal before 2021 is over. Last of all, as a top innovator, Illumina stays firmly committed to defending our intellectual property around the world. We obtained injunctions against BGI for patent infringement in the U.S., Germany, U.K., Spain, Sweden and Finland. We continue to feel confident that our IP portfolio provides robust protection for Illumina's innovation both now and far into the future. And with that, I'll hand things over to Sam.

Sam Samad

executive
#3

Thanks, Francis. Like Francis mentioned, our fourth quarter revenue hit a record, rising modestly from the same period a year ago to $953 million, with sequencing up 1% offsetting an 8% drop in microarrays. Sequencing revenue overall set a record at $846 million, accounting for 89% of total revenue in Q4 2020 and up 19% from the third quarter. Consumables for sequencing rose 5% versus the year-ago period and 20% quarter over quarter. Instruments for sequencing came in about even with last year and climbed 29% sequentially. Service and other sequencing revenue fell 15% against the prior year period because of IVD partnership revenue recognized a year earlier. Turning to regions. The Americas posted 14% sequential growth. Compared with the same quarter last year, revenue in the region declined 2%, mainly from onetime technology access fees tied to an IVD partnership plus lower DTC revenue, partly offset by sequencing consumables. The Americas achieved record sequencing product revenue in Q4, led by clinical customers. EMEA turned in record revenue of $285 million, up 34% sequentially and 2% year over year, fueled by strong instrument revenue from NovaSeq. We additionally saw some customers in emerging countries receiving their first NovaSeq shipments. Greater China rose 16% sequentially and 3% year over year to $96 million, and it recorded its best sequencing instrument revenue quarter since 2017, helped in part by rising hospital demand. After Q4, we also unveiled the Sequoia Capital China genomics incubator, extending our other incubator work in Silicon Valley and the U.K. Together, we'll partner with top entrepreneurs in China to launch genomic start-ups that develop breakthrough genomics applications and clinical sequencing solutions. Lastly, APJ revenue came to $77 million, up 24% sequentially and 5% versus the prior year period. For the entire year, the region was about flat against 2019, with full year growth in sequencing consumables. Shifting to gross margin and operating expenses. I'll focus on non-GAAP results, which include stock-based compensation. I'd urge you to look at the GAAP reconciliation of these non-GAAP measures, available in today's release and the supplementary data on our website. Note that all later mentions of net income and earnings per share refer to results attributable to Illumina shareholders. As anticipated, non-GAAP gross margin of 66.9% fell roughly 50 basis points sequentially. Versus a year ago, fourth quarter non-GAAP gross margin dropped 330 basis points, largely because of a onetime inventory write-down in Q4, onetime IVD partnership revenue in the year-ago quarter and higher freight costs tied to COVID-19. Non-GAAP operating expenses totaled $439 million, up $74 million sequentially, as expected, reflecting the additional week in Q4, variable compensation expenses and other investments. Non-GAAP operating margin came in at 20.9%, down from 21.4% in the third quarter. Non-GAAP other income of $20 million was $13 million higher sequentially, driven by gains on short-term investments sold as we repositioned our investment portfolio for the anticipated funding of the GRAIL acquisition. Our non-GAAP tax rate came in at 18.4%, which rose versus the prior quarter, and that was because of a discrete charge tied to a tax structure initiative taken in Q4. The quarter-over-quarter step-up in our tax rate for Q4 was also affected by discrete tax benefits recorded in the third quarter of 2020 that related to prior year return adjustments. Looking at the fourth quarter of 2020, GAAP net income reached $257 million, equal to $1.75 per diluted share, while non-GAAP net income came to $179 million, or $1.22 per diluted share. Turning to cash flow and balance sheet items. Operating cash flow totaled $406 million. DSO stands at 50 days, versus 53 days in the previous quarter, which was driven by revenue linearity. Capital expenditures in the fourth quarter were $62 million, and free cash flow amounted to $344 million. During Q4 we bought back $280 million of stock; we closed out the year holding roughly $3.5 billion across cash, cash equivalents and short-term investments. Our weighted average diluted share count for the quarter came to 147 million. Shifting now to 2021 guidance. For the full year 2021, we anticipate revenue growth between 17% and 20%, or $3.79 billion to $3.89 billion, which works out to an increase of roughly $599 million at the midpoint. Across the full year of 2021, using the midpoint of our revenue guidance range, we anticipate sequencing revenue to expand by about 20%. That figure includes growth in sequencing consumables of around 20%; for sequencing system revenue, we anticipate 33% growth year-over-year, propelled by NovaSeq placements stemming from ongoing HiSeq conversions and uptake of v1.5 reagents, along with NextSeq placements from NextSeq 2000 and DX demand, while arrays should grow approximately 5% against 2020; for the full year, we anticipate non-GAAP gross margin to improve modestly over 2020, reflecting greater leverage from higher volumes and cost savings initiatives, partly offset by product mix and IVD partnership revenue in the first quarter of 2020. We anticipate operating margin of roughly 24% in 2021. As volumes rise and freight charges return to normal, we anticipate both gross and operating margins to strengthen during the second half of 2021 and land above the full year average. We anticipate other income to be roughly $40 million below 2020, owing to the gains in the fourth quarter of 2020, lower interest rates and shorter duration investments ahead of the expected close of the GRAIL acquisition; we anticipate GAAP earnings per share between $4.76 and $5.01 and non-GAAP earnings per share between $5.10 and $5.35; and we anticipate diluted shares outstanding of approximately 147 million in 2021. Shifting to the first quarter of 2021, we are lifting our earlier expectations, and we now anticipate high single-digit revenue growth against the first quarter of 2020. Our outlook is for non-GAAP gross margin to improve on a sequential basis; non-GAAP operating expenses to decline sequentially, in line with typical seasonality; non-GAAP other income to come in significantly lower than the fourth quarter of 2020, reflecting the onetime gain on short-term investments we discussed earlier, and consequently, we anticipate non-GAAP EPS to be slightly higher than the fourth quarter of 2020. I'll now return the call to Francis for his closing comments.

Francis deSouza

executive
#4

2021 has begun on a powerful note for us. Our core business is showing momentum, and we're fulfilling a vital function in the new surveillance push that's required to combat the pandemic. Over the last few months, with the arrival of newer, more threatening SARS-CoV-2 variants, awareness has grown that COVID monitoring is needed worldwide, and nations such as the U.K., Australia, Canada and Germany are taking the lead when it comes to rolling out national surveillance systems; in the U.S. A proposed budget package includes $1.75 billion earmarked for the CDC to carry out, broaden and enhance work on genome sequencing, mutation identification and tracking how viruses—SARS-CoV-2 among them—spread. One of the crucial weapons in this pandemic fight is surveillance built on sequencing. And it's growing evident that sequencing and surveillance are moving into the mainstream when it comes to defending against infectious disease. The worldwide surveillance framework now under construction will play a key part in spotting upcoming outbreaks, covering coronaviruses, antimicrobial resistance and bioterrorism. Illumina takes pride in leading this vital effort. We also want to extend congratulations to Nobel Laureate and Illumina Board member Dr. Frances Arnold, who has been appointed as Co-Chair of the U.S. President's Council of Advisors in Science and Technology; in our view, this recent selection of deeply seasoned scientists reflects the administration's commitment to science, genomics included, as a means of bettering life across the U.S. for all. Lastly, we still anticipate completing the GRAIL acquisition during this year's second half, which will let us assist in speeding up adoption of early cancer detection screening and unlock the biggest genomics application to date by a wide margin. We look forward to GRAIL's Q2 launch of Galleri. A tremendous range of opportunities lies before us. And there's never been a more thrilling moment to work in genomics and at Illumina. I'll now ask the operator to begin the Q&A.

Dan Brennan

analyst
#5

Thanks. Francis, I have two things to ask. First, that's really aimed at Sam — it's about the profit outlook for the coming year. A pretty big chunk of operating expense is baked into it, and there isn't much operating leverage coming through, so I'd like you to take us through the reasoning, since that opening forecast caught us off guard. Then, Francis, for my second item, I'd appreciate it if you could take us through how you're thinking about the cadence across next year, specifically regarding how well NovaSeq has performed up to now. Dan, when it comes to those HiSeq owners who are still with us and have yet to make the switch, could you shed a bit more light on what assumptions are built into the plan — specifically around the new v1.5 release, how many of them you figure will move over, and what that does to your guidance?

Sam Samad

executive
#6

Sure, Dan, and thanks. This is Sam — I hope things are going well for you. Let me spend a moment on the EPS outlook, which sits at $5.10 to $5.35 for this year. What that reflects is an operating margin of about 24%, and it does include some growth on the OpEx side. There's also a one-time element tied to stock-based compensation, which we mentioned at JPMorgan when we gave the guidance. It involves two plans — the '19 and '20 plans — that the pandemic hit hard, and we're adjusting the targets for them. As a result, there's a one-time catch-up charge in 2021 of roughly $50 million to $55 million, and that accounts for a pretty substantial share of the OpEx increase. On top of that, we keep investing in our platforms, our technologies, and our assays — something we're dedicated to. R&D remains a major priority for us. Looking ahead, Dan, what we're aiming for is steady gains in the way our operating margin leverages up, so we can return to the kinds of operating margin figures we saw in '19 — roughly 30%. Getting there won't happen overnight. Even so, we're committed to pushing operating leverage forward by keeping a close watch on G&A spending and cutting back — or at minimum ensuring those costs rise more slowly than revenues do; at the same time, we'll keep putting money into R&D and, to a degree, commercial efforts too. Even so, our long-range goal remains restoring operating leverage. Beyond that, once we're through the pandemic, we anticipate the year's latter six months will bring better gross margin and operating margin than the first six months, and those figures should also top the results for the entire year in both gross margin and operating margin.

Francis deSouza

executive
#7

Great, thanks Sam. Dan, I’ll address your question about NovaSeq for this year and also speak to the HiSeq customers who are still with us and how we’re viewing that in 2021. Let me begin by noting that we’re heading into the year with considerable momentum behind NovaSeq. The 1.5 version reagents for NovaSeq, which came out in August, truly performed well when it came to unlocking demand elasticity in the high-throughput portion of the market. As we’ve mentioned, as we enter this year, we’re coming off a Q4 in which, during our initial quarter of selling those 1.5 reagents, NovaSeq consumables set a record, rising mid-teens versus the prior year — so quite strong on the consumables side. We also noted that Q4 brought our second-largest order for NovaSeq in terms of bookings. The largest came when NovaSeq first launched in 2017. So on both the instrument side and the consumables side, we’re coming off a very strong Q4, and we’re entering this year with a very strong pipeline and a solid backlog after the orders that arrived in Q4. So as we look at this year, we see 2 sources of demand for NovaSeq. First — and we discussed this in Q4 as well — because of 1.5, we’re seeing demand really unlock from customers who are new to high throughput. Consider that in Q4, more than half of bookings went to customers new to high throughput. So once again, that new pricing is opening the market for new customers to enter. The second source of NovaSeq demand as we enter this year is the HiSeq customers who remain. As we’ve noted, out of our original HiSeq base, 320 customers have still not started the upgrade cycle. And with the lower pricing on 1.5, these usually smaller core labs can now access a NovaSeq. Looking at the pricing, a HiSeq 2500 customer only needs to run roughly 4 high-output kits per month to justify a NovaSeq’s list price within a year. Also, with the 1.5 release, we lengthened consumables’ shelf life from 3 months to 6 months, so they don’t need to sequence as often to make the upgrade worthwhile. And last, the new 35-cycle S4 kits also bring counting method to NovaSeq now, which mattered to those labs. Put all of that together, and we’re entering this year with strong momentum on the NovaSeq side, and that’s what we expect to drive orders this year. In fact, we anticipate another strong year of NovaSeq orders as we move into 2021.

Tycho Peterson

analyst
#8

A few fast questions. Regarding Q4, did any consumable stocking occur? We heard about that from a competitor last night. Also, how much of that record order book came from catch-up purchases rather than the acceleration and adoption Francis just described, which the flow cell is driving? Then I want to know why margins came in so weak. You had the price adjustments, the inventory write-down and stock-based comp, yet it feels like something else was going on. Are you perhaps pulling some spending forward? Second, turning to the outlook, it's encouraging that you're raising the Q1 guidance compared with what you shared at our conference. Did something shift in your view? The earlier guide of down 9% to 10% clearly didn't make much sense, so this matches what I believe people expected, but what caused the change? And Francis, on a wider note, could you address the surveillance opportunity — how material might it become, and what portion do you expect to be handled through short read versus long read?

Sam Samad

executive
#9

Sure. Let me take a few of those points you raised first, Tycho, and I'll have Francis speak to surveillance. There's quite a bit there, so hopefully I get to all of it. On Q4 stocking: we enjoyed a very strong quarter. Nothing out of the ordinary appeared beyond the typical year-end pattern. Budgets normally get reset late in Q4 — academic budgets at year-end. So apart from the usual annual pattern, no unusual stocking showed up in Q4. We confirm this by examining activity on our sequencers. We review the activity and data available to us across all connected active sequencers. Indeed, activity levels rose strongly in Q4, with clinical returning to and exceeding pre-pandemic growth, and research now essentially at pre-pandemic levels. That's good to see, and it confirms no unusual stocking happened late in Q4. On gross margin, we've discussed the causes, Tycho. The pandemic still weighs on us. Freight remains a factor in Q4. We recorded the one-time write-down on certain inventory, roughly a one percentage point negative hit to gross margin. Mix also played a role in Q4, since instruments were strong that quarter. Those are what affected margins in Q4. For the first quarter, we're looking for margins to get better, then keep getting better as 2021 goes on, and during the back half of the year, in fact, they should be—like I mentioned before—higher than the average for the whole year and beginning to return to what we refer to as our typical range of 70% or more—not exactly at 70% but in that vicinity during the back half. So we certainly anticipate that once we begin moving past the limitations caused by the pandemic, which led to increased freight costs and other elevated expenses; as for the first quarter guidance, we're happy to be lifting our first quarter guidance given what we're observing. We're observing strength in the business. We're observing strength in activity levels. Once more, it's too early to speak in specifics. It's been 4 weeks since the year began. But all that we're observing when it comes to orders is truly encouraging. So we're happy with how the business has begun.

Francis deSouza

executive
#10

Yes. I'd like to add to what Sam said. So Tycho, you're correct — for Q1, this is a meaningful increase compared with what we had anticipated when we spoke at JPMorgan. And what we told everyone at JPMorgan was the usual pattern for our company and for others in our sector: thanks to the capital cycle, revenue typically declines going from Q4 into Q1. That was our call, and we told you to expect us to be level with Q1 of the prior year. But even in just the first few weeks of this quarter, we're observing considerably more momentum, and as Sam mentioned, that momentum is originating in our core business — and we're tracking two things: not only orders, but activity levels as well. As we came out of Q4 and moved into Q1, we're seeing robust activity levels on the clinical side of the business and on the research side too. So at this point, it has become evident to us that rather than matching last year, we will be up high single digits, which puts us fairly near where we stood in Q4. That's not typical for this business, but it truly reflects the strength we're seeing when it comes to incoming orders. Of course, plenty of the year remains, so we're keeping our full-year guidance unchanged, though certainly with strength in Q1. On surveillance — we've been discussing this for roughly a year now. The concept is that alongside deploying testing infrastructure to combat this pandemic, you also need surveillance infrastructure to grasp how the virus is spreading across geographies and how it's mutating. And details about mutations are critical for confirming that the tools we're deploying against the pandemic — the diagnostics, the vaccines, the therapies — will keep working. And once the outbreak emerged around Christmas — the B-117 variant in the U.K. and then the South African variant — that's what really made people grasp that the surveillance infrastructure is indeed necessary. So it added little revenue in Q4, and we've included only a modest amount for Q1. But the activity is visible, isn't it? You can see it in COG-UK. You can see it in countries worldwide — France, Germany, Italy, Spain, and really across the globe. And we anticipate that will keep going throughout this year as countries build out their surveillance infrastructures. And that will be a durable surveillance infrastructure. We'll need it going forward to alert us to the next pandemic, to alert us to bioterrorist attacks, antimicrobial resistance. And what's fascinating is that Illumina's technology is uniquely well suited to this need, and the reason is our unmatched accuracy. We have the ability to produce at the largest possible scale. We can hit the necessary per-sample price. And we've also got the first approved product that our customers can actually put to use. So all of those factors converged. You're going to see that reflected in the figures, correct? At the very start, our sequencer was the one deployed in Wuhan; after that in Shanghai, to release the initial viral genome. Vaccine makers relied on Illumina sequencing data to create the vaccines, the mRNA vaccines in use today. That happened thanks to how accurate Illumina sequencing is; and today, when you consider the big initiatives like COG-UK and several others, Illumina sequencers are the ones being employed, given the scale we're able to reach along with throughput and turnaround time. So if you check the counts of genomes in GISAID, for instance, you'll find that the overwhelming bulk of the data there, the overwhelming bulk of genomes that have been sequenced, came from Illumina sequencers. So this is very thrilling, very significant, beginning right now.

Doug Schenkel

analyst
#11

I'll go through these fast. Regarding how much NovaSeq gets used, the yearly consumables pull-through for NovaSeq, as I recall, exceeded $1.2 million during Q4. As for 2021, at least regarding the assumptions baked into your guidance, I think it's $1.1 million to $1.2 million per box. I'd like to know what's behind the forecast of somewhat reduced utilization compared with Q4, given that Q4 had no unusual stocking. A few possibilities come to mind — perhaps it's simply that we're early in the year, with uncertainty particularly as the pandemic winds down. Perhaps it's the assumption that many more boxes will be installed, which can initially weigh on pull-through on an average basis. And/or it might relate to the v1.5 reagent pricing having an effect, so any specifics on that assumption would be useful; and the other item I wanted to raise was GRAIL. Are you still expecting PATHFINDER data in Q1? Is that still true? At what point would registration studies begin? And is there anything you can say about how things are going with self-insured employers, closed health care systems and/or concierge systems?

Sam Samad

executive
#12

Sam here. I'll begin with your pull-through question, then hand it to Francis for GRAIL. Yeah, I think you nailed it with what you said about pull-through. We had a very, very strong pull-through, I'd say, in Q4 — $1.2 million per instrument; we were back above pre-pandemic levels, in fact at the top end of the guidance range for pre-pandemic levels. With the v1.5, we do expect — it will spur significant HiSeq conversion among those 320 remaining HiSeq customers, so they'll begin moving over to NovaSeq as well. That has, I'd say, a quite modest downward effect on pull-through, though on the other side the large centers will push pull-through up; and — but as you noted, we're still in a pandemic year. The first 6 months are still expected to essentially be a pandemic reality, so to speak; and right now, I think it's wise for our guidance and our expectation to be the $1.1 million to $1.2 million range. But we're very encouraged by Q4.

Francis deSouza

executive
#13

Yeah. And on the GRAIL front, if I could jump in — there's nothing fresh to report. What that tells you is GRAIL remains on schedule for its PATHFINDER data, just as they stated at JPMorgan when they made their Q1 announcement, and they remain on schedule to launch Galleri during Q2. We're aware they're making headway with health systems as well as self-insured employers. Nothing has been announced by them as of yet; however, I can tell you, for instance, that here at Illumina we are proceeding along the path to bring the GRAIL test to our own employees during the back half of this year. And through that effort, our team has been in conversations with additional employers who are likewise working through the process with them. The major news, clearly, on the health system front was what came out regarding the NHS, and that pilot remains on track to begin this year. And just to remind everyone, that involves 165,000 tests they've committed to run, with the intention afterward — provided things go well — of running 1 million tests in 2024 and subsequently doing a population-wide rollout.

Puneet Souda

analyst
#14

You're looking at sequencing consumables up 20% this year, and I'm just trying to get a handle on it, because you're listing quite a few things that should push growth. Easy comparisons, clearly, the new chemistry, the $600 genome discount we saw in Q4 — that's clearly creating the demand elasticity you'd have anticipated. On top of that, COVID sequencing is rising, COVID variants are showing up. There are instrument purchases happening after the pandemic, and cancer patients could be coming back as they get their vaccines in 2021; plus MRD and screening, and those trials are picking up steam as well. Given everything you've laid out, I'd like to understand the reasoning behind that 20% figure — why take a conservative stance there? Also, before anything else, I'm grateful for the road map you provided about the product enhancements you anticipate. That said, I'm wondering how we ought to interpret that in light of the customer event on the horizon. Last thing — could we discuss MRD as well? It's turned into a fresh priority for GRAIL. Two rivals already operate in that space, so what's your strategy for standing out? And what are your expectations when it comes to those competing players? Clearly, they're also using Illumina machines to process samples. So regarding the MRD sector, what kind of acceleration do you foresee during the next one to three years? Thank you for fielding these.

Sam Samad

executive
#15

Yes, thank you, Puneet. I trust things are going well for you; this is Sam speaking. I'll address the sequencing consumable matter first, and afterward I'll have Francis weigh in on both the road map topic and the MRD one. We're expecting sequencing consumables to grow 20% this year, and there are several reasons for that—some quite favorable tailwinds exist within the business, along with core business strength, which is what pushes us toward that figure. Like you said, when it comes to getting more market access and coverage—whether that's for NIPT or for genetic conditions—we are certainly observing expansion. On the oncology front, comprehensive genomic profiling is growing, and v1.5 represents a strong launch. Regarding the COVID variant piece, Puneet, we haven't actually baked a meaningful effect from it into our guidance. From a surveillance standpoint, that's something we find quite encouraging. We're clearly seeing momentum there, though it's still a little soon to put a full-year figure on it. So I'd say it isn't materially reflected in our guide. Also, keep in mind something else: I don't mean to keep repeating myself, but this is still a year shaped by the pandemic. For the first half of the year, we expect to remain in pandemic conditions, so I wouldn't describe this as a typical year. For the second six months, though, we're hopeful about coming out of the pandemic, especially with the progress we're seeing in vaccination numbers. That said, all the points you brought up are fair. Hopefully this gives you a clearer picture.

Francis deSouza

executive
#16

All right, then. There are a couple of items I want to cover. I'll discuss the customer event, then the road map, and then the GRAIL MRD test. So, a customer event is indeed on the schedule. This will be, in a sense, our inaugural worldwide virtual customer gathering for this year, and it'll take place toward the end of April. It's coming together as a fantastic event. We've lined up some wonderful speakers, and we've organized tracks aimed at various portions of our customer base. There will be one track, for instance, focused on population sequencing, where we'll bring together several of the biggest population sequencing efforts from across the globe so they can exchange insights and gain knowledge from one another. We'll follow the same approach for oncology testing, and so forth. My guess is that what you were driving at, Puneet, is whether we intend to make any announcements during the customer event. I've stated publicly before that my preference would be to unveil products to customers rather than to bankers. That said, I clearly cannot reveal what our product road maps hold. Our company's policy is not to preannounce products. What we did unveil not long ago was the P1 flow cell. For the NextSeq, we unveiled ICA, the connected analytics platform, at JPMorgan, and it's gaining genuinely good momentum in population sequencing work; and of course, there's the v1.5. So you'll simply need to remain watchful regarding what gets announced and when; regarding GRAIL — just MRD broadly, plus the GRAIL MRD test — we're extremely enthusiastic about what an MRD test can do for patients; our belief is that it will better the lives of cancer patients, helping them detect recurrence sooner. This will be a significant market and represents a major opportunity. But as you noted, 2 of our customers already have MRD tests. We'll stand behind them. We're determined to see them become hugely successful, since this is both a vital segment and a sizable one within genomics applications too; so we'll keep doing all we can to ensure their success. We're also enthusiastic about GRAIL's MRD test. GRAIL takes a somewhat different angle in how they approach MRD. What sets GRAIL's efforts apart from those of certain other companies is that a number of the tests available on the market right now are tailored to individual patients. Here's how that works: you generate a tumor profile for a given patient's cancer, drawing on the tissue sample obtained from that patient, and afterward you build the test for that specific cancer patient; then you — and from that point on you administer it as a blood test. So it's a really strong test, quite significant, quite revolutionary, yet since you're collecting a tissue sample and creating a test tailored to each patient, it does require a certain amount of time. GRAIL takes a different route. Their MRD test is built upon their screening test, meaning it's not specific to each patient — it's the one blood test utilized for screening that they also apply to MRD. That ought to substantially shorten the timeline for getting that test to a patient, and no tissue biopsy is needed; therefore, in our view they hold a distinctive position in the market, and we're eager to launch that as well and offer patients an option. During the past several weeks, GRAIL made some notable partnership announcements. So at JPMorgan, we discussed how GRAIL revealed collaborations with Amgen, AstraZeneca, Bristol-Myers Squibb as partners for its MRD test — clearly an outstanding group of partners, and it keeps demonstrating solid momentum regarding the advancement of GRAIL's test.

Derik De Bruin

analyst
#17

Two questions, then. The first thing I'd like to get into is this: could you give us some sense of what you're expecting, culturally speaking, from the mid-range platforms — NextSeq and MiSeq — as we head into '21? I appreciate the detail you gave on NovaSeq, but hearing something on that front would be useful, especially regarding NextSeq, since you're putting more of those boxes out on the 2000 and 1000 side. Then the second item follows up on what Doug asked. Could you say a bit about GRAIL, in terms of how you plan to handle sales and marketing, and how you'll reach customers? I mean, given that your existing business isn't really aimed at that market, do you have to go build or acquire a bigger primary care sales force? I'm basically wondering about your commercialization plans and what you're thinking for the go-to-market approach.

Sam Samad

executive
#18

Let me take the pull-through one first — and thanks, Derik, by the way — and then Francis can address GRAIL. On pull-through for mid-throughput and low throughput, Derik: to begin with NextSeq, at this point we won't provide a pull-through figure for NextSeq. There are numerous variables at play, as you're aware, when it comes to NextSeq 2000, which launched relatively recently, at the close of Q1 last year, plus NextSeq 1000 entering the picture later in the year. Those things are going to affect NextSeq 550, and we're still working out how the potential pull-through might look for NextSeq 2000, so offering a guidance range for the pull-through expectation there would be premature at this point. Turning to low throughput, MiSeq and MiniSeq too. MiSeq took a hit from the pandemic in 2020. Normally we provide a guidance range of 40,000 to 45,000 per box on MiSeq; the pandemic hurt it in 2020, so it came in well under that, and then toward the close of 2020 it began nearing the bottom of that range, in the high 30s. So at present, for MiSeq, we're looking at roughly 35,000 to 40,000 for MiSeq pull-through per box in 2021. As for MiniSeq, the range is typically 20,000 to 25,000, and for MiniSeq we expect to land at the low end of it.

Francis deSouza

executive
#19

Appreciate that, Sam. Now I'd like to turn to how GRAIL will be taken to market. To begin, once the acquisition closes, our plan is for GRAIL to operate as a standalone division. That means it will have its own infrastructure covering everything from start to finish. As for GRAIL's go-to-market approach — and you've begun to catch a few hints of it — it won't necessarily involve standing up a large sales force calling directly on physicians. GRAIL's initial strategy is a B2B one: selling to health systems, national health systems such as the arrangement they described with the NHS, and additionally integrated health systems across the U.S., concierge health systems, and self-insured employers. That makes it an enterprise sale, a B2B sale — much like what we do here at Illumina, clearly somewhat different, though we too maintain an enterprise sales force. That is what we intend for GRAIL moving ahead. While there may be a degree of patient advocacy and education involved, I'd note that one edge GRAIL holds over certain tests available on the market right now is that theirs is a blood test, which doesn't call for much prodding to get individuals to comply with a test they must take home, for instance. So the model they're employing is somewhat distinct. And again, they're already using that model at present — they hold something like an IDE from the FDA, and they're delivering results back to patients within some truly top-tier health care systems, such as the Cleveland and so forth. So that's the model they're in the process of refining. That's the model set to be rolled out at the NHS. And that's the model we anticipate will carry on going forward.

Patrick Donnelly

analyst
#20

Thanks. I had a few questions focused on China. In the fourth quarter, you recorded the largest instrument revenue there in several years. I believe you mentioned observing additional adoption on the hospital side. Could you give us a little more detail about what you're seeing in that market? It would also be helpful to hear an update regarding the competitive landscape. Have you noticed any shifts in China when it comes to how competitors are behaving? And finally, this is probably for Sam, regarding the guidance, what assumptions are you making about China for the outlook?

Sam Samad

executive
#21

Sure. Let me take the final question first since it's straightforward. We anticipate China revenue growth that is greater than our total company revenue growth, so I'd describe it as somewhat higher than our overall revenue growth. We're also seeing quite encouraging developments in China, as shown by the Q4 performance and the instrument figure you brought up. But perhaps Francis can offer some further detail.

Francis deSouza

executive
#22

Yeah, let me jump in on that. Clearly, we're quite optimistic about China — we anticipate its growth will outpace the total company in 2021. What's behind that? Several factors. First, we're beginning to witness what you might call the next phase of clinical-market adoption there. More hospitals are bringing sequencing into their own labs. That wave began building last year and has definitely gained momentum as we moved into this year. It helps explain why Q4 was our strongest quarter for instruments since 2017, the year NovaSeq launched. Hospitals starting to adopt sequencing and move it into their labs contributed to that. We're also seeing COVID prompt some sequencing purchases. As we've mentioned, we were summoned to Wuhan in December 2019, and we've been part of their pandemic response ever since. That factors into this business, and it's also part of a lasting surveillance infrastructure now under construction. Beyond that, our long-term enthusiasm for the China opportunity remains. You saw, for instance, that we announced a partnership with Sequoia Capital China, among the leading venture capital firms there, to establish a genomic incubator in China aimed at spurring the next generation of exciting genomics applications built on Illumina's sequencing technology.

Sung Ji Nam

analyst
#23

Just two fast questions from me. First, returning to the surveillance chance for COVID and future other uses — I'm not sure whether it's premature, but could you perhaps discuss what the potential market might look like down the road? And if you can't, is this an infrastructure roughly at the same scale as what flu surveillance has right now? Or does it involve a far bigger effort? Then my second question: you both mentioned the flow cell enhancement, that order-of-magnitude gain, producing about 90% in cost reductions on the flow cell. How does that show up in the overall all-in cost for each genome?

Francis deSouza

executive
#24

Let me begin, then, by addressing the surveillance chance. Sizing that surveillance chance is premature, I'd say — that's the brief response; yet regarding how to approach it, done properly, I believe it's considerably larger than what flu gives us at present; and clearly, from many angles, this pandemic served as a wake-up moment. One illustration: at some point in late Q1, early Q2, we spoke with U.S. government officials, and it became clear the coronavirus had been spreading across the U.S. for weeks — perhaps months — while people died, and we hadn't even realized it was there. That's an enormous wake-up call, since it matters not only for a coronavirus pandemic but also carries consequences for bioterrorism surveillance, for instance. Thus the wake-up call tells us: look, we require the surveillance infrastructure, and we require a global one. It must be genomic-based, and it must monitor emerging antimicrobial resistance, new pathogens, bioterrorism. That scope is considerably larger than the flu tracking occurring now. Another fascinating dynamic unfolding: this is unquestionably a public health infrastructure, vital for public health, without question. Yet it's likewise a defense infrastructure; and the 2 get funded quite differently, correct? As you're aware, public health swings from panic to starvation, right? So there's the panic, infrastructure gets built, and then maybe the funding follow-through doesn't always arrive. Defense doesn't work that way. Consequently this will combine both; it will be a public health infrastructure, and it will form part of the national defense infrastructure. So considered over the long term, its scope is certainly considerably larger in thinking than what flu involves for us now.

Sam Samad

executive
#25

Absolutely. So Sung Ji, about that ninety percent decrease — Francis laid out some genuinely thrilling items on the innovation and technology road maps over at JPMorgan. And when we say a ninety percent cut when it comes to cost, what we're really getting at is not something we sell right now, but rather the road map in front of us and the technologies we already have, which will turn into a product that gets us to a $100 genome and even below that, in terms of what it costs for each genome.

Tejas Savant

analyst
#26

Just one quick housekeeping item regarding COVID surveillance, Francis; regarding that P1 flow cell, my understanding is it goes out during the latter six months of this year. Given the emphasis on monitoring both within the United States and internationally, plus the demand for a NextSeq choice with reduced throughput, is there any way you could move that up on the launch schedule? Then for my second question, I want to ask about GRAIL. Previously, you hinted at the idea that there might be some kind of arrangement where risk is shared, and Illumina would bear responsibility — or perhaps other insurers would bear responsibility — for an increase in total diagnostic testing expenses after Galleri gets rolled out, as a way to motivate clients to join pilots. Have you made any actual headway yet when it comes to putting those kinds of arrangements in place? Or has it not been long enough?

Francis deSouza

executive
#27

Understood. Allow me to address the P1 inquiry first, and afterward I'll touch on the, I suppose, partnerships. Let me begin by noting that at this point you're aware of my perspective, correct, in that we possess this remarkable lineup of offerings that the engineers at our company are developing. And with each single one, I wish we could receive it sooner, because when I consider the effect — and we allocate 18% of our revenue toward R&D — it's an astonishing collection of items that the team is creating; they are moving as quickly as possible to release the product at the quality level required, particularly considering the crucial work our clients perform using our products. So even though I would very much like to, the truth is we cannot accelerate P1, despite the fact that I know there is tremendous, tremendous desire for it. That applies to our whole portfolio as well. And I believe you're correct, it will truly — it will truly be quite significant even for surveillance purposes. I think your next question concerned the partnerships we intended to establish with other clients in the oncology diagnostics field as we aim to enter screening. And we are advancing with those clients. We have executed supply agreements, long-term supply agreements, with a number of those clients and are maintaining ongoing discussions with the rest. Thus our pledge is to keep providing them with the technology required and ensure they receive completely equal access to the technologies we bring to market moving forward. In certain instances, those agreements extend beyond 10 years. And that benefits our clients. It benefits us as well.

Juliet Cunningham

executive
#28

Absolutely. I really appreciate all of you for those excellent questions. Just a quick note — a recording of today's call can be found starting tomorrow on our site, under Investor Relations; we're eager to share news about how things are going once Q1 has wrapped up. All the best.

Operator

operator
#29

That wraps up the conference call for today, everyone. We appreciate your participation. You're free to disconnect at this point.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Illumina, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Illumina, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Illumina, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.